Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

C4 Therapeutics (CCCC) Other Operating Expenses (2024 - 2025)

C4 Therapeutics' Other Operating Expenses history spans 2 years, with the latest figure at $10.7 million for Q3 2025.

  • For Q3 2025, Other Operating Expenses changed N/A year-over-year to $10.7 million; the TTM value through Dec 2025 reached $10.7 million, up 340.42%, while the annual FY2025 figure was $10.7 million, N/A changed from the prior year.
  • Other Operating Expenses reached $10.7 million in Q3 2025 per CCCC's latest filing, up from $2.4 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $10.7 million in Q3 2025 to a low of $2.4 million in Q1 2024.